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Abstract
Introduction: We report the case of a 62-year-old woman diagnosed with sarcomatoid renal cell carcinoma.
Case presentation: A 62-year-old Asian woman presented with macroscopic hematuria. A histological and
immunohistochemical study of a tumor biopsy specimen led to a suspected diagnosis of sarcomatoid renal cell
carcinoma. She underwent surgical tumor resection that included her left kidney. A histological and
immunohistochemical study of the resected tumor confirmed the diagnosis of sarcomatoid renal cell carcinoma.
The pathological stage was pT3bpN2, and multiple lung metastases were detected (pT3bpN2cM1; stage IV).
Our patient was classified as “poor risk” according to the Memorial Sloan Kettering Cancer Center risk criteria.
Interferon-α was administered as adjuvant therapy, and her lung metastases remained stable. However, a
computed tomography scan and bone scintigraphy 2 years later revealed multiple bone metastases. External beam
radiotherapy was performed for the bone metastases. Despite continuing interferon-α during radiotherapy, multiple
skull and liver metastases appeared. Oral administration of the tyrosine kinase inhibitor axitinib was initiated as a
second-line therapy, and our patient achieved a stable state for 11 months. As the liver metastases progressed and
meningeal dissemination newly appeared, oral administration of the mammalian target of rapamycin inhibitor
everolimus was initiated as a third-line therapy. Our patient remains alive 71 months after diagnosis and has
maintained a comparatively good quality of life.
Conclusion: A literature review revealed that metastatic sarcomatoid renal cell carcinoma has very poor prognosis,
with a survival of <1 year despite systemic therapy. Our patient in this present case achieved long-term survival, a
rare incidence worthy of report.
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Introduction
The sarcomatoid variant of renal cell carcinoma (RCC)
features a spindle-cell phenotype and has been reported
to have a poor prognosis compared with other histo-
logical types of RCC [1–3]. Some reports have noted
that the prognosis of patients with sarcomatoid RCC
(SRCC) is poor even after tyrosine kinase inhibitor treat-
ment [1]. However, we report our experience with a case
of metastatic sarcomatoid RCC (mSRCC) in which the
patient achieved long-term survival following multi-
disciplinary treatment. We also discuss the relevant
literature.
Case presentation
A 62-year-old Asian woman visited a urological office
in August 2009 with a complaint of macroscopic
hematuria. Following an intensive examination, she was
suspected to have a left renal tumor, for which she visited
our department in September 2009.
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Blood biochemistry data indicated anemia, thrombocy-
tosis, prolonged prothrombin time, hyperkalemia, and
elevated levels of alkaline phosphatase, gamma-glutamyl
transpeptidase, and lactate dehydrogenase. Her total
albumin-corrected serum calcium level was within nor-
mal limits. A microscopic urine analysis revealed slight
microscopic hematuria and pyuria. Urine cytology was
negative for malignancy.
Dynamic computed tomography (CT) revealed a
tumor with a 13-cm diameter in her left kidney (Fig. 1)
and tumor embolism in her left renal vein. Lymph node
swelling was also detected at her left renal hilus. In
addition, lung metastases were strongly suspected fol-
lowing a lung CT scan.
A CT-guided biopsy of the left renal tumor was per-
formed, and a histopathological examination indicated
SRCC. Renography yielded right and left renal function
rates of 53.5 mL/min and 30.4 mL/min, respectively.
Bone scintigraphy showed no evidence of metastasis.
She was diagnosed with a suspected left-side SRCC at
clinical stage T3bN2M1 (PUL), according to the TNM
classification.
Our patient underwent transabdominal left radical
nephrectomy. The pathological diagnosis was SRCC with
a >50 % sarcomatoid component; a clear-cell type com-
ponent was also detected (Fig. 2). The final diagnosis
was SRCC (pT3bpN2cM1), and she was considered to
be “poor risk” according to the Memorial Sloan Kettering
Cancer Center risk criteria.
Interferon-α (3 million U, three times per week) was
initially administrated as an adjuvant systemic therapy.
Although the multiple lung metastases subsequently
disappeared, a follow-up CT scan 2 years after surgery
revealed multiple bone and skull metastases (Fig. 3a).
The bone agent zoledronic acid was administrated, and
external beam radiotherapy was performed for the bone
and skull metastases. Although we were able to control
the bone metastases, multiple liver metastases subse-
quently appeared. We then administered the tyrosine
kinase inhibitor axitinib (10 mg/day) as a second-line
therapy, as well as denosumab for the bone metastases.
Meningeal dissemination was first detected during
follow-up 11 months after switching to axitinib and was
treated with stereotactic irradiation. Because our patient’s
disease was considered progressive, we administered the
mammalian target of rapamycin (mTOR) inhibitor evero-
limus (10 mg/day) as a third-line therapy. The multiple
liver metastases, meningeal dissemination, and multiple
bone metastases were well controlled at 16 months after
everolimus administration (Fig. 3b). Our patient remains
alive with controlled disease 71 months after the initial
diagnosis and has maintained a comparatively good qual-
ity of life, despite receiving long-term treatment.
Discussion
SRCC was defined in the 2004 World Health Organization
classification of renal tumors as any histologic type of
RCC containing foci of high-grade malignant spindle cells.
Some evidence indicates an increased risk associated with
a sarcomatoid component comprising 5–10 % of total
tumor volume [4, 5], suggesting that even a low level of
sarcomatoid differentiation might be clinically relevant
and should be included in pathology reports.
mSRCC had a very poor prognosis in the pre-targeting
therapy era. For example, Molina et al. reported 63
cases of sarcomatoid-variant RCC at the Memorial Sloan
Kettering Cancer Center, of which 47 were clear cell RCC,
and 16 were non-clear cell RCC. The median progression-
free and overall survival durations in that study were 3
months and 10 months, respectively, despite the adminis-
tration of systemic therapy [1].
Zhang et al. reported 204 cases of sarcomatoid-variant
RCC treated via nephrectomy [2]. Of these, 168 patients
died from SRCC at a mean of 1.7 years post-surgery
Fig. 1 Contrast-enhanced computed tomography examination prior
to treatment. A tumor with a 13-cm diameter was detected in the
left kidney
Fig. 2 A specimen of the resected tumor. Large, abnormal
multinucleated cells or pleomorphic/spindle cancer cells are visible
in a hematoxylin-eosin stained tumor section. Magnification ×200
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(median 0.8 years; range 0.1–29.4 years). In a further
comparison of patients with ≥30 % versus <30 % sar-
comatoid differentiation, patients in the former group
were significantly more likely to die (hazard ratio 1.52;
p = 0.018).
In terms of histochemistry, hypoxia-inducible factor
(HIF)-1α is well known to induce vascular endothelial
growth factor (VEGF), which in turn correlates with
tumor progression. Accordingly, Tickoo et al. repor-
ted high levels of HIF-1α expression in patients with
SRCC [4].
On the other hand, some reports have noted the relation-
ship between sarcomatoid features and the epithelial-to-
mesenchymal transition (EMT), an important metastatic
process, in RCC [3]. For example, Boström et al. mentioned
that transforming growth factor (TGF)-β expression corre-
lated with EMT in patients with SRCC [6]. Furthermore,
Lamouille et al. demonstrated a relationship between
TGF-β and mTOR complex 2, which is required for
cell migration and invasion in vitro [7].
Regarding our present case, the clinical course demon-
strates the efficacy of switching from interferon-α to
molecular-targeting agents. Unfortunately, evidence re-
garding the effectiveness of axitinib or everolimus for
mSRCC is currently lacking.
However, given the fact that VEGF, a target of the
multi-tyrosine kinase inhibitor axitinib, is expressed at
high levels in SRCC, and that mTOR, a target of everoli-
mus, possibly correlates with EMT in mSRCC, it is rea-
sonable to treat mSRCC with these molecular-targeting
agents.
The systemic effects of bone-modifying agents such as
zoledronic acid or denosumab on cancer-specific sur-
vival remain controversial, and the effects on mSRCC
are also unknown. Although the sarcomatoid component
comprised >50 % of the RCC in our present case, we
were able to maintain a comparatively stable disease
through multidisciplinary treatment.
Conclusions
We have described our experience with a case of
mSRCC; to the best of our knowledge, the long survival
duration (currently 71 months) is rare. Multidisciplinary
treatments, that is, a combination of radical surgery, cyto-
kine therapy, molecular-targeting therapy, radiotherapy,
and bone-modifying agent therapy, were therefore effect-
ive for long-term survival in this case. Further research is
needed to determine the correlation between treatment
and molecular mechanisms in mSRCC.
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